دورية أكاديمية
Reduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
| العنوان: | Reduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy |
|---|---|
| المؤلفون: | Gauthier, J, Castagna, L, Garnier, F, Guillaume, T, Socié, G, Maury, S, Maillard, N, Tabrizi, R, Marchand, T, Malfuson, J-V, Gac, A-C, Gyan, E, Mercier, M, BEGUIN, Yves, Delage, J, Turlure, P, Marcais, A, Nguyen, S, Dulery, R, Bay, J-O, Huynh, A, Daguindau, E, Cornillon, J, Regny, C, Michallet, M, Peffault de Latour, Régis, Yakoub-Agha, I, Blaise, D |
| المصدر: | Bone Marrow Transplantation, 52, 689-696 (2017) |
| بيانات النشر: | Nature Publishing Group, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N = 34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N = 31, 91%) or a RIC (N = 3, 9%) followed by post-transplant cyclophosphamide. After adjustment for significant covariates, MMUD and CB were associated with significantly lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR) = 2.02, P = 0.03 and HR = 2.43, P = 0.009, respectively) compared withHAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with posttransplant cyclophosphamide from HAPLO donors. Our findings suggest they should be favoured over MMUD and CB in this setting. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article peer reviewed |
| اللغة: | English |
| Relation: | urn:issn:0268-3369; urn:issn:1476-5365 |
| DOI: | 10.1038/bmt.2016.34 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/210424 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.210424 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1038/bmt.2016.34 |
|---|